氢溴酸樟柳碱注射液治疗中重度急性缺血性脑卒中的有效性和成本-效益研究

Study on the effectiveness and cost-benefit of anisodine hydrobromide injection in the treatment of moderate and severe acute ischemic stroke

目的:评价氢溴酸樟柳碱注射液治疗急性缺血性脑卒中的有效性、安全性和成本-效益。方法:2018年8月-2020年1月收治急性缺血性脑卒中患者186例,随机分为两组,各93例。观察组运用氢溴酸樟柳碱注射液治疗;对照组接受丁苯酞氯化钠注射液治疗。比较两组临床疗效、改良Rankin(mRS)评分、美国国立卫生院神经功能缺损量表(NIHSS)评分、不良反应发生率及成本-效益。结果:试验组治疗总有效率高于对照组,差异有统计学意义(P<0.05);试验组治疗后NIHSS评分和mRS评分均低于对照组,差异有统计学意义(P<0.05);试验组成本-效益优于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:氢溴酸樟柳碱注射液治疗中重度急性缺血性脑卒中,安全、有效、经济。

Objective:To evaluate the efficacy,safety and cost-benefit of anisodine hydrobromide injection in the treatment of acute ischemic stroke.Methods:From August 2018 to January 2020,186 cases of patients with acute ischemic stroke were enrolled,they were randomly divided into two groups with 93 cases in each group.The observation group was treated with anisodine hydrobromide injection.The control group was treated with butyphthalide sodium chloride injection.The clinical efficacy,mRS scale score,NIHSS scale score,the incidence rate of adverse reactions and cost-benefit were compared between the two groups.Results:The total effective rate of treatment in the experimental group was higher than that in the control group,the difference was statistically significant(P<0.05).After treatment,the NIHSS scale score and m RS scale score in the experimental group were lower than those in the control group,the differences were statistically significant(P<0.05).The cost-benefit of the experimental group was better than that of the control group.The incidence rate of adverse reactions between the two groups was compared,the difference was not statistically significant(P>0.05).Conclusion:Anisodine hydrobromide injection is safe,effective and economical in the treatment of moderate and severe acute ischemic stroke.